keyword
MENU ▼
Read by QxMD icon Read
search

Insuline Glargin

keyword
https://www.readbyqxmd.com/read/29657375/comparison-of-glycemic-control-between-continuous-regular-insulin-infusion-and-single-dose-subcutaneous-insulin-glargine-injection-in-medical-critically-ill-patients
#1
Rungsun Bhurayanontachai, Tharittamon Rattanaprapat, Chanon Kongkamol
Background and Aims: This study aimed to compare glycemic control between continuous intravenous regular insulin infusion and single-dose subcutaneous insulin glargine injection in medical critically ill patients. Subjects and Methods: A prospective noninferiority study was conducted in medical critically ill patients who developed hyperglycemia and required regular insulin infusion by the Intensive Care Unit glycemic control protocol. The eligible patients were switched from the daily regular insulin requirement to single-dose subcutaneous insulin glargine injection by a 100% conversion dose...
March 2018: Indian Journal of Critical Care Medicine
https://www.readbyqxmd.com/read/29656504/efficacy-and-safety-of-myl-1501d-versus-insulin-glargine-in-patients-with-type-1-diabetes-after-52-weeks-results-of-the-phase-3-instride-1-study
#2
Thomas C Blevins, Abhijit Barve, Bin Sun, Michael Ankersen
AIMS: Insulin glargine, a long-acting human insulin analogue, allows for once-daily basal use in patients with type 1 diabetes mellitus (T1DM). MYL-1501D is a proposed insulin glargine biosimilar. MATERIALS AND METHODS: Safety and efficacy of MYL-1501D and reference insulin glargine were evaluated in INSTRIDE 1: a 52-week, open-label, randomized, phase 3 study in patients with T1DM. The primary objective was to determine whether once-daily MYL-1501D was noninferior to once-daily insulin glargine when administered in combination with mealtime insulin lispro based on change in glycosylated hemoglobin (HbA1c ) from baseline to week 24...
April 15, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29652279/a-commentary-effects-on-glargine-insulin-on-glycemic-control-in-patients-with-diabetes-mellitus-type-ii-undergoing-off-pump-coronary-artery-bypass-graft
#3
Soumya Sankar Nath, Pravin Kumar Das
No abstract text is available yet for this article.
April 2018: Annals of Cardiac Anaesthesia
https://www.readbyqxmd.com/read/29652278/effects-of-glargine-insulin-on-glycemic-control-in-patients-with-diabetes-mellitus-type-ii-undergoing-off-pump-coronary-artery-bypass-graft
#4
Hemang Gandhi, Alpesh Sarvaia, Amber Malhotra, Himanshu Acharya, Komal Shah, Jeevraj Rajavat
Background: The prevalence of diabetes mellitus in patients requiring coronary artery bypass grafting (CABG) is noticeably high (20%-30%). These patients have inferior perioperative outcome, reduced long-term survival, and high risk of recurrent episodes of angina. To improve perioperative outcome surgical unit defined satisfactory glycemic control is desired during this period. Hence, the aim of our study is to compare the efficacy of glargine insulin combination with continuous human insulin infusion for perioperative glycemic control in patients with diabetes undergoing CABG...
April 2018: Annals of Cardiac Anaesthesia
https://www.readbyqxmd.com/read/29651052/management-of-glycemic-variation-in-diabetic-patients-receiving-parenteral-nutrition-by-continuous-subcutaneous-insulin-infusion-csii-therapy
#5
Feng-Fei Li, Wen-Li Zhang, Bing-Li Liu, Dan-Feng Zhang, Wei Chen, Li Yuan, Mao-Yuan Chen, Xiao-Fang Zhai, Jin-Dan Wu, Xiao-Fei Su, Lei Ye, Hong-Yong Cao, Jian-Hua Ma
To compare the continuous subcutaneous insulin infusion (CSII) or insulin glargine based multiple injections (MDI) therapy on glycemic variations in diabetic patients receiving PN outside of intensive care settings. This was a single-center, randomized, open-label trial. Patients with type 2 diabetes (T2D) who were receiving parenteral nutrition (PN) were recruited. After baseline data were collected, recruited patients were then randomized 1:1 to a CSII group or a MDI group. All patients were subjected to a 4-day retrospective Continuous Glucose Monitoring (CGM)...
April 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29649539/switching-to-insulin-glargine-300-u-ml-is-duration-of-prior-basal-insulin-therapy-important
#6
Riccardo C Bonadonna, Eric Renard, Alice Cheng, Andreas Fritsche, Anna Cali, Lydie Melas-Melt, Guillermo E Umpierrez
AIMS: To assess the impact of duration of prior basal insulin therapy on study outcomes in people with type 2 diabetes mellitus receiving insulin glargine 300 U/mL (Gla-300) or insulin glargine 100 U/mL (Gla-100) for 6 months. METHODS: A post hoc patient-level meta-analysis of data from the EDITION 1 and 2 studies. Outcomes included: HbA1c , percentage of participants with ≥1 confirmed or severe hypoglycaemic event at night (00:00-05:59 h) or any time (24 h), and body weight change...
April 9, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29649221/long-acting-insulin-analogues-for-type-1-diabetes-an-overview-of-systematic-reviews-and-meta-analysis-of-randomized-controlled-trials
#7
Fernanda O Laranjeira, Keitty R C de Andrade, Ana C M G Figueiredo, Everton N Silva, Mauricio G Pereira
BACKGROUND: The comparison between long acting insulin analogues (LAIA) and human insulin (NPH) has been investigated for decades, with many randomized controlled trials (RCTs) and systematic reviews giving mixed results. This overlapping and contradictory evidence has increased uncertainty on coverage decisions at health systems level. AIM: To conduct an overview of systematic reviews and update existing reviews, preparing new meta-analysis to determine whether LAIA are effective for T1D patients compared to NPH...
2018: PloS One
https://www.readbyqxmd.com/read/29620817/evaluating-the-managed-care-implications-of-longer-acting-basal-insulin-analog-therapies
#8
Tripp Logan, Bianca Daisy
Diabetes, particularly type 2 diabetes (T2D), has become an epidemic in the United States, with a significant portion of patients unable to meet recommended glycemic targets. All individuals with type 1 diabetes (T1D) and a significant majority of those with T2D will ultimately require insulin therapy. However, there are several barriers to its use. The introduction of the new, ultra-long-acting basal insulins degludec and glargine U-300, and the single-injection combinations of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide, offer options that may overcome several of those barriers, including the high risk of hypoglycemia, glycemic variability, and relatively short duration of action...
March 2018: American Journal of Managed Care
https://www.readbyqxmd.com/read/29619751/basal-bolus-insulin-therapy-with-gla-300-during-hospitalization-reduces-nocturnal-hypoglycemia-in-patients-with-type-2-diabetes-mellitus-a-randomized-controlled-study
#9
Fumitaka Okajima, Yuko Nakamura, Yuji Yamaguchi, Yuki Shuto, Katsuhito Kato, Hitoshi Sugihara, Naoya Emoto
INTRODUCTION: Although reduction in the incidence of nocturnal hypoglycemia, as estimated by symptom or self-monitored plasma glucose, was shown to be more pronounced with 300 units/mL insulin glargine (Gla-300) than with 100 units/mL insulin glargine (Gla-100) in type 2 diabetes patients, the exact frequency of nocturnal hypoglycemia estimated with continuous glucose monitoring (CGM) has not been reported. METHODS: Forty patients with type 2 diabetes who were admitted for glycemic control with basal-bolus insulin therapy (BBT) were randomized into the Gla-100 and Gla-300 groups...
April 4, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29619381/efficacy-and-safety-of-insulin-glargine-300-u-ml-versus-100-u-ml-in-diabetes-mellitus-a-comprehensive-review-of-the-literature
#10
REVIEW
Hernando Vargas-Uricoechea
To achieve good metabolic control in diabetes and maintain it in the long term, a combination of changes in lifestyle and pharmacological treatment is necessary. The need for insulin depends upon the balance between insulin secretion and insulin resistance. Insulin is considered the most effective glucose-lowering therapy available and is required by people with type 1 diabetes mellitus to control their blood glucose levels; yet, many people with type 2 diabetes mellitus will also eventually require insulin therapy, due to the progressive nature of the disease...
2018: Journal of Diabetes Research
https://www.readbyqxmd.com/read/29619208/conversion-from-insulin-glargine-u-100-to-insulin-glargine-u-300-or-insulin-degludec-and-the-impact-on-dosage-requirements
#11
Scott M Pearson, Jennifer M Trujillo
Background: We wanted to determine whether basal insulin requirements change when patients transition from insulin glargine U-100 (Gla-100) to insulin glargine U-300 (Gla-300) or insulin degludec. Methods: This study involved subjects seen in the University of Colorado Health Endocrine Clinic who were transitioned from Gla-100 to either Gla-300 ( n = 95) or insulin degludec ( n = 39). The primary outcome was the difference between baseline Gla-100 dose and dose of Gla-300 or insulin degludec prescribed after first follow-up visit within 1-12 months...
April 2018: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29615978/genome-wide-analyses-identify-filamin-a-as-a-novel-downstream-target-for-insulin-and-igf1-action
#12
Daniel Aizen, Metsada Pasmanik-Chor, Rive Sarfstein, Zvi Laron, Ilan Bruchim, Haim Werner
Insulin analogs were developed to improve diabetes therapy. However, certain modifications introduced into the insulin molecule were shown to enhance their affinity to the insulin-like growth factor-1 receptor (IGF1R). Most tumors, including endometrial cancers, express high levels of IGF1R. The present study was aimed at identifying the entire set of genes that are differentially activated by insulin glargine or detemir, in comparison to insulin and IGF1, in Type 1 and Type 2 endometrial cancer cell lines (ECC-1 and USPC-1, respectively)...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29610753/insulin-degludec-u100-is-associated-with-lower-risk-for-severe-and-symptomatic-hypoglycemia-as-compared-with-insulin-glargine-u100-in-subjects-with-type-1-diabetes
#13
EDITORIAL
Anastasios Tentolouris, Ioanna Eleftheriadou, Nikolaos Tentolouris
No abstract text is available yet for this article.
February 2018: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29610159/use-of-insulin-glargine-in-the-management-of-neonatal-hyperglycemia-in-an-elbw-infant
#14
Min J Hwang, Robert Newman, Katherine Philla, Elizabeth Flanigan
Neonatal hyperglycemia is common in extremely low birth weight (ELBW) infants because of physiologic stress, exogenous glucose infusion, and postnatal corticosteroid therapy for hypotension, adrenal insufficiency, and pulmonary immaturity. The use of long-acting insulin glargine has been described in the treatment of transient neonatal diabetes in the premature infant, but in these reports is a lack of regard to its use in the treatment of iatrogenic neonatal hyperglycemia. We present the case of an ELBW infant with significant hyperglycemia that was refractory to usual treatment but demonstrated a favorable response to long-acting subcutaneous insulin glargine...
April 2018: Pediatrics
https://www.readbyqxmd.com/read/29609864/long-acting-insulin-analogs-and-cancer
#15
REVIEW
L Sciacca, V Vella, L Frittitta, A Tumminia, L Manzella, S Squatrito, A Belfiore, R Vigneri
AIMS: Hyperinsulinemia is a recognized risk factor for cancer and plays a major role for the increased cancer incidence in diabetic patients. Whether insulin analogs, and particularly long-acting analogs, worsen the pro-cancer effect of excess insulin is still controversial. DATA SYNTHESIS: In this paper we summarize the biological bases for the potential detrimental effect of long-acting analogs on cancer cells and review the in vitro and in vivo evidence on this issue...
February 24, 2018: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/29596514/characterisation-of-insulin-analogues-therapeutically-available-to-patients
#16
Gary G Adams, Andrew Meal, Paul S Morgan, Qushmua E Alzahrani, Hanne Zobel, Ryan Lithgo, M Samil Kok, David T M Besong, Shahwar I Jiwani, Simon Ballance, Stephen E Harding, Naomi Chayen, Richard B Gillis
The structure and function of clinical dosage insulin and its analogues were assessed. This included 'native insulins' (human recombinant, bovine, porcine), 'fast-acting analogues' (aspart, glulisine, lispro) and 'slow-acting analogues' (glargine, detemir, degludec). Analytical ultracentrifugation, both sedimentation velocity and equilibrium experiments, were employed to yield distributions of both molar mass and sedimentation coefficient of all nine insulins. Size exclusion chromatography, coupled to multi-angle light scattering, was also used to explore the function of these analogues...
2018: PloS One
https://www.readbyqxmd.com/read/29569224/author-correction-clinical-benefit-of-basal-insulin-analogue-treatment-in-persons-with-type-2-diabetes-inadequately-controlled-on-prior-insulin-therapy-a-prospective-noninterventional-multicenter-study
#17
Jelica Bjekić-Macut, Teodora Beljić Živković, Radivoj Kocić
In the original publication, values of the doses of insulin glargine, the most commonly used basal insulin analogue under the 'Discussion' section was incorrectly published.
March 22, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29566586/efficacy-and-safety-of-basal-insulin-glp-1-receptor-agonist-used-in-combination-for-type-2-diabetes-management
#18
Delilah McCarty, Alaina Olenik, Bryan P McCarty
PURPOSE: The purpose of this article is to review the efficacy, safety, and place in therapy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (IGlarLixi) in the treatment of type 2 diabetes mellitus. SUMMARY: Type 2 diabetes is a condition affecting nearly 30 million American adults. Management of type 2 diabetes is complex and multifactorial. Using medications targeted at a variety of the physiologic defects known to contribute to the development of type 2 diabetes allows for a patient-specific approach to care...
January 1, 2018: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/29560778/correction-to-lane-et-al-insulin-degludec-versus-insulin-glargine-u100-for-patients-with-type-1-or-type-2-diabetes-in-the-us-a-budget-impact-analysis-with-rebate-tables
#19
Ws Lane, James Weatherall, Jens Gundgaard, Richard F Pollock
No abstract text is available yet for this article.
March 21, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29548798/clinical-perspectives-from-the-begin-and-edition-programmes-trial-level-meta-analyses-outcomes-with-either-degludec-or-glargine-300u-ml-vs-glargine-100u-ml-in-t2dm
#20
R Roussel, R Ritzel, E Boëlle-Le Corfec, B Balkau, J Rosenstock
AIMS: To explore comparative glycaemic control and hypoglycaemia incidence with insulin degludec 100U/mL (IDeg) or insulin glargine 300U/mL (Gla-300) versus glargine 100U/mL (Gla-100) in trial-level meta-analyses of phase 3a clinical trials including people with type-2 diabetes. METHODS: Meta-analyses of HbA1c , fasting plasma glucose (FPG), average 24h self-measured plasma glucose (SMPG), pre-breakfast SMPG and hypoglycaemia incidence and rate, using data from the BEGIN (IDeg) and EDITION (Gla-300) insulin development programmes, were performed...
February 19, 2018: Diabetes & Metabolism
keyword
keyword
49211
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"